ZYRTEC® Clinical Data
In 2 large clinical studies
ZYRTEC® significantly improved quality of life (QoL) in adult seasonal allergic rhinitis (SAR) patients vs placebo*1-3
In 2 clinical studies, patients receiving ZYRTEC® reported 56% to 63% greater improvements in overall RQLQ scores compared with placebo
The Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) is a validated measurement of overall QoL. These studies used the 28-item RQLQ, which measured 7 domains: activity limitation, sleep problems, nose symptoms, eye symptoms, non–hay fever symptoms, practical problems, and emotional function.‡
In Study 1,2 ZYRTEC® also significantly reduced patients’ impairment at work and with daily activities§||2
Significant reduction from baseline at Week 2 was seen vs placebo in impairment at work and activity impairment (P<0.05), using the WPAI-AS questionnaire.
In a large clinical study of adult PAR patients
80% greater improvement in QoL vs placebo¶1
Patients receiving ZYRTEC® reported significantly greater improvements in overall RQLQ scores compared with placebo
The RQLQ is a validated measurement of overall QoL. The study used the 24-item RQLQ which measured: activity limitation, sleep problems, nose symptoms, non–hay fever symptoms, practical problems, and emotional function.#
*Two multicenter, randomized, double-blind, placebo-controlled studies including 1254 adult SAR patients. Primary study endpoint measured changes in overall RQLQ score from baseline.
†Endpoint = last postbaseline observation.
‡Adult RQLQ assessed domains on a 7-point (0-6) rating scale.4
§Randomized, placebo-controlled, 2-week study of SAR adult patients (N=431 for each treatment group).
||WPAI-AS=Work Productivity and Activity Impairment-Allergy Specific (WPAI-AS) questionnaire measures performance based on impairment at work (limitations in the amount or kind of work done, work accomplished, or work done as carefully as usual) and activity impairment (limitations in usual activities, such as work around the house, shopping, child care, exercising, etc).
¶Multicenter, randomized, double-blind, placebo-controlled study including 316 adult PAR patients. Primary study endpoint measured changes in overall RQLQ score from baseline.
#Adult RQLQ assessed domains on a 7-point (0-6) rating scale.5
References: 1. Data on file, Johnson & Johnson Consumer Inc., McNeil Consumer Health Division. 2. Murray JJ, Nathan RA, Bronsky EA, Olufade AO, Chapman D, Kramer B. Comprehensive evaluation of cetirizine in the management of seasonal allergic rhinitis: impact on symptoms, quality of life, productivity, and activity impairment. Allergy Asthma Proc. 2002;23(6):391-398. 3. Noonan MJ, Raphael GD, Nayak A, et al. The health-related quality of life effects of once-daily cetirizine HCI in patients with seasonal allergic rhinitis: a randomized double-blind, placebo-controlled trial. Clin Exp Allergy. 2003;3(3):351-358. 4. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjuntivitis. Clin Exp Allergy. 1991;21(1):77-83. 5. Juniper EF, Guyatt GH, Andersson B, Ferrie PJ. Comparison of powder and aerosolized budesonide in perennial rhinitis: validation of rhinitis quality of life questionnaire. Ann Allergy. 1993;70(3):225-230.
Need samples or patient resources?
See the ZYRTEC® difference
Compare ZYRTEC® vs other OTC oral antihistamines.
See the complete family of ZYRTEC® products.